Printer Friendly

TELIOS PHARMACEUTICALS EXPANDS TELIO-DERM(TM) CLINICAL TRIALS Wound Healing Product Shows Encouraging Results

 TELIOS PHARMACEUTICALS EXPANDS TELIO-DERM(TM) CLINICAL TRIALS
 Wound Healing Product Shows Encouraging Results
 SAN DIEGO, Dec. 6 /PRNewswire/ -- Telios Pharmaceuticals Inc. today announced that clinical testing of Telio-Derm(TM) -- its first product designed to speed the healing of chronic wounds -- has been expanded to multi-center studies of three types of chronic dermal ulcers.
 Based on encouraging results from early clinical studies, Telios recently began a multi-center trial in patients with leg ulcers resulting from sickle-cell disease and another in patients with diabetic foot ulcers. The third multi-center study, which began last year in patients with venous leg ulcers, has been expanded to 25 sites across the United States.
 A product of Telios' "matrix peptide" technology, Telio-Derm is a topically administered viscous gel containing a proprietary peptide, or protein fragment, which promotes the attachment of new skin cells to the wound site. Animal studies have shown that Telio-Derm acts as a temporary scaffold to which new cells can attach and grow until dermal healing is completed. Clinical testing has been under way since late 1989 and is aimed at speeding wound healing in three indications -- severe thermal burns, skin ulcers and surgical incisions.
 More than 3.5 million Americans suffer from severe skin ulcers. If left untreated these wounds can become infected and expand in size, requiring aggressive measures such as hospitalization, skin grafting or amputation of the affected limb. Of this group, leg ulcers afflict at least one million diabetics whose risk of amputation is 15 times higher than that of non-diabetics. Half of these patients will undergo a second amputation in one to three years. Patients with sickle-cell anemia are also at risk for painful, debilitating leg ulcers.
 Founded in 1987, Telios Pharmaceuticals is developing therapeutic products based on the company's matrix-peptide technology. Studies by its scientists have shown that the extracellular matrix -- a network of molecules that surrounds all cells in the body -- is critical to the way the body heals itself and combats disease. The company is developing a broad portfolio of products aimed at selectively modifying cell/matrix interactions for a wide range of clinical needs, including dermal and ophthalmic wound healing, and critical fibrotic diseases of the kidneys and lungs.
 -0- 12/6/91
 /CONTACT: Audrey L. Dickason of Telios Pharmaceuticals Inc., 619-597-6109; or Charles Versaggi of Versaggi & Associates, 408-358-4162 for Telios Pharmaceuticals Inc./ CO: Telio Pharmaceuticals, Inc. ST: California IN: MTC SU: PDT


DB -- SJ002 -- 9972 12/06/91 08:30 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 6, 1991
Words:408
Previous Article:THE SOFTWARE TOOLWORKS INC. COMMENTS ON REPORT REGARDING INSIDER TRANSACTIONS
Next Article:SYNERGEN TO BEGIN THREE NEW CLINICAL TRIALS
Topics:


Related Articles
TELIOS PHARMACEUTICALS INC. SELLS 2.5 MILLION SHARES OF COMMON STOCK IN INITIAL PUBLIC OFFERING
TELIOS ANNOUNCES THIRD QUARTER 1992 RESULTS
DECORIN MAY PREVENT PROGRESSION OF KIDNEY DISEASE UTAH AND CALIFORNIA SCIENTISTS REPORT
TELIOS ANNOUNCES NORSK HYDRO DECISION
TELIOS PHARMACEUTICALS INC. OFFERS 4.5 MILLION SHARES OF COMMON STOCK
TELIOS ANNOUNCES FOURTH QUARTER 1992 RESULTS
TELIOS COMMENCES ADVANCED PHASE II STUDY FOR OCUNEX OPHTHALMIC SOLUTION
JOURNAL ARTICLES REPORT UNIQUE SAFETY PROFILE AND PROPRIETARY STRUCTURE OF TELIOS' ANTI-THROMBOTIC PEPTIDE
TELIOS PHARMACEUTICALS ANNOUNCES PRELIMINARY RESULTS OF DIABETIC FOOT ULCER STUDY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters